HHS, Johnson & Johnson Expand Previous Agreement To Support R&D For Coronavirus Vaccine Candidate
- November 16, 2020
Reuters (11/14, Contractor) reported HHS and Johnson & Johnson “have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development.” Under the expanded agreement, Johnson & Johnson “will commit approximately $604 million and the HHS Department’s Biomedical Advanced Research and Development Authority will commit about $454 million to support the Phase 3 ENSEMBLE trial evaluating Janssen’s investigational [SARS-CoV-2] vaccine candidate as a single dose in up to 60,000 volunteers worldwide.”